Who are Ibuprofen, Hydrocodone/Acetaminophen, Omeprazole's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ibuprofen-hydrocodone-acetaminophen-omeprazole.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Ibuprofen, Hydrocodone/Acetaminophen, Omeprazole — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ibuprofen, Hydrocodone/Acetaminophen, Omeprazole (Ibuprofen, Hydrocodone/Acetaminophen, Omeprazole) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID + opioid analgesic + proton pump inhibitor combination. Area: Pain Management / Gastroenterology.

marketed NSAID + opioid analgesic + proton pump inhibitor combination COX-1/COX-2 (ibuprofen); mu-opioid receptor (hydrocodone); H+/K+-ATPase (omeprazole) Pain Management / Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Ibuprofen, Hydrocodone/Acetaminophen, Omeprazole (Ibuprofen, Hydrocodone/Acetaminophen, Omeprazole) — University of Chicago. This is a combination therapy regimen using ibuprofen (NSAID), hydrocodone/acetaminophen (opioid/analgesic), and omeprazole (proton pump inhibitor) to manage pain while protecting the gastrointestinal tract.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ibuprofen, Hydrocodone/Acetaminophen, Omeprazole TARGET	Ibuprofen, Hydrocodone/Acetaminophen, Omeprazole	University of Chicago	marketed	NSAID + opioid analgesic + proton pump inhibitor combination	COX-1/COX-2 (ibuprofen); mu-opioid receptor (hydrocodone); H+/K+-ATPase (omeprazole)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NSAID + opioid analgesic + proton pump inhibitor combination class)

University of Chicago · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ibuprofen, Hydrocodone/Acetaminophen, Omeprazole — Competitive Intelligence Brief. https://druglandscape.com/ci/ibuprofen-hydrocodone-acetaminophen-omeprazole. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab